-
LianBio Initiates Phase I Study of SHP2 Inhibitor BBP-398 in China
•
Sino-US biotech LianBio has announced the first patient dosing in a Phase I clinical study for its SHP2 inhibitor BBP-398 in Chinese patients with advanced solid tumors. This marks a significant step forward in the development of BBP-398, which targets the SHP2 protein-tyrosine phosphatase. SHP2 links growth factor, cytokine, and…
-
Ascentage Pharma Gains CDE Approval for Phase I Study of APG-5918
•
Suzhou-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the Center for Drug Evaluation (CDE) to conduct a multi-center, open-label, dose escalation and expansion Phase I study. The study will assess the safety, pharmacokinetics, and efficacy of its embryonic ectoderm development (EED) inhibitor APG-5918. The drug…
-
3SBio Receives NMPA Review for Pediatric ITP Thrombopoietin Filing
•
China-based 3SBio Inc. (HKG: 1530) has announced that the National Medical Products Administration (NMPA) has accepted another market filing for its recombinant thrombopoietin for the treatment of persistent or chronic primary immune thrombocytopenia (ITP) in children or adolescents. This marks a significant step forward in expanding the therapeutic indications for…
-
Betta Pharmaceuticals’ BPI-D0316 Shows Promise in Phase II/III Lung Cancer Study
•
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced the summary report of a Phase II/III study for its third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) BPI-D0316. The study evaluated the drug as a first-line treatment for naïve locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR…
-
Haisco’s HSK16149 Accepted for Review by NMPA for Diabetic Neuropathic Pain
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that a market approval filing for its drug candidate HSK16149, intended for the treatment of diabetic peripheral neuropathic pain (DPNP), has been accepted for review by the National Medical Products Administration (NMPA). HSK16149 is an in-house Category 1 drug being…
-
Liaoning Chengda’s ACYW135 Meningococcal Vaccine Receives NMPA Clearance
•
China’s Liaoning Chengda Biotechnology Co., Ltd (SHA: 688739) has announced that it has received clinical clearance from the National Medical Products Administration (NMPA) for its ACYW135 meningococcal polysaccharide conjugate vaccine. The vaccine is designed to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis of groups A, C, Y, and W135.…
-
Zhaoke Ophthalmology Enrolls First Patients for ZKY001 in Phase II Trials
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) spin-off Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the enrollment of the first patients for its ZKY001 in a Phase II clinical study in transepithelial photorefractive keratectomy (TPRK). The study will enroll 120 patients across 10 centers. Additionally, a separate Phase II clinical…
-
MicuRx Pharmaceuticals Doses First Patient in China for MRX-8 Trial
•
Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals (SHA: 688373) has announced the first patient dosing in a Phase I clinical study in China for its MRX-8, a new drug against gram-negative drug-resistant bacteria. This marks a significant milestone in the development of MRX-8, which aims to address the growing challenge of…
-
Zhifei Bio Initiates Global Study for Omicron-Delta COVID-19 Vaccine in Uzbekistan
•
China-based Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd has announced the initiation of a global clinical study for its Omicron-Delta variant recombinant COVID-19 protein vaccine in Uzbekistan. This marks a significant step in the development of the second-generation vaccine, which targets the Omicron and Delta variants. Previous Clinical StudiesPreviously, Zhifei Bio chose…
-
Cyramza Prescribed in China for Advanced Gastric Cancer
•
Cyramza (ramucirumab) was first prescribed on November 6, 2022, at the Zhongshan Hospital in Shanghai and Beijing Cancer Hospital, marking a new treatment option for second-line advanced gastric cancer patients in China. This milestone follows the drug’s market approval in March 2022 for treating second-line advanced metastatic gastric cancer in…
-
Merck’s Keytruda Receives 10th Indication Approval in China for TNBC
•
US-based Merck Sharp & Dohme’s (MSD, NYSE: MRK) programmed death-1 (PD-1) inhibitor Keytruda (pembrolizumab) has obtained its 10th indication approval from China’s National Medical Products Administration (NMPA). The drug can now be used to treat early high-risk triple negative breast cancer (TNBC) with tumors expressing PD-L1 (CPS ≥ 20) in…
-
Qilu Pharma’s QL1706 Shows Promise in Phase II Cervical Cancer Study
•
China-based Qilu Pharmaceutical has published the latest results from a Phase II clinical study for QL1706, a dual-targeted antibody against programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). The findings were presented at the Chinese Society of Clinical Oncology (CSCO) annual meeting. Study Design and ResultsPrevious clinical studies…
-
Ascletis Pharma Presents Phase I Study Results for ASC43F at AASLD
•
China-based Ascletis Pharma Inc. (HKG: 1672) made a poster presentation detailing the abstract of a Phase I study for ASC43F in a single dose to treat non-alcoholic steatohepatitis (NASH) at The Liver Meeting 2022 of the American Association for the Study of Liver Diseases (AASLD). The presentation highlighted the drug’s…
-
Ji Xing Pharmaceuticals’ Omecamtiv Mecarbil Accepted for Review by CDE
•
Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, announced that a market filing for its investigational omecamtiv mecarbil has been accepted for review by the Center for Drug Evaluation (CDE). The small molecule is a potential first-in-class cardiac myosin activator being developed as a treatment for heart failure with reduced…
-
Innovent Biologics’ Tafolecimab Shows Strong LDL-C Reduction in Phase III Study
•
China-based Innovent Biologics, Inc. (HKG: 1801) announced the results of the Phase III CREDIT-1 study for tafolecimab (IBI306), a recombinant fully human anti-PCSK-9 monoclonal antibody (mAb), in Chinese patients with non-familial hypercholesterolemia (non-FH). The findings were presented at the American Heart Association (AHA) Scientific Sessions 2022 as an e-poster (VP173).…
-
Jiangsu Yahong Initiates Phase III Study for Hexvix in Bladder Cancer Detection
•
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced the enrollment of the first subject in a prospective, subject-controlled, multi-center Phase III clinical study. The study aims to assess the additional detection rate and safety of Hexvix, a bladder cancer diagnosis and postoperative detection product,…
-
Betta Pharmaceuticals’ BPI-452080 Accepted for Review by NMPA
•
China’s Betta Pharmaceuticals (SHE: 300558) has announced that a clinical trial filing for its Category 1 drug candidate BPI-452080 has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant step forward in the development of the drug, which is designed to treat advanced solid…
-
Qilu Regor’s RGT-264 Phosphate Tablets Approved for Phase I Study
•
China-based biotech Qilu Regor Therapeutics Inc has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a Phase I study. The study will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of its RGT-264 phosphate tablets in patients with advanced solid tumors. RGT-264 ProfileRGT-264 is a…
